Pastva, O.; Chrastinova, L.; Bockova, M.; Kotlin, R.; Suttnar, J.; Hlavackova, A.; Stikarova, J.; Ceznerova, E.; Cermak, J.; Homola, J.; Dyr, J.E.

Hsp70 trap assay for detection of misfolded subproteome related to myelodysplastic syndromes

[rok vydání 2019, impact factor 6.785 ]

Garelius, H.K.; Johnston, W.T.; Smith, A.G.; Park, S.; de Swart, L.; Fenaux, P.; Symeonidis, A.; Sanz, G.; Čermák, J.; Stauder, R.; Malcovati, L.; Mittelman, M.; van de Loosdrecht, A.A.; van Marrewijk, C.J.; Bowen, D.; Crouch, S.; de Witte, T.J.; Hellström-Lindberg, E.

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

[rok vydání 2016, impact factor 6.754 ]

Stojkov, K.; Silzle, T.; Stussi, G.; Schwappach, D.; Bernhard, J.; Bowen, D.; Čermák, J.; et al.

Guideline-based indicators for adult patients with myelodysplastic syndromes

[rok vydání 2020, impact factor 6.686 ]

Oster, H.S.; Crouch, S.; Smith, A.; Yu, G.; Shrkihe, B.A.; Baruch, S.; Kolomansky, A.; Ben-Ezra, J.; Naor, S.; Fenaux, P.; Symeonidis, A.; Stauder, R.; Cermak, J.; et al.

A predictive algorithm using clinical and laboratory parameters may assist in ruling out and in diagnosing MDS

[rok vydání 2021, impact factor 6.686 ]

Szikszai, K.; Krejcik, Z.; Klema, J.; Loudova, N.; Hrustincova, A.; Belickova, M.; Hruba, M.; Vesela, J.; Stranecky, V.; Kundrat, D.; Pecherkova, P.; Cermak, J.; Jonasova, A.; Dostalova Merkerova, M.

LncRNA profiling reveals that the deregulation of H19, WT1-AS, TCL6, and LEF1-AS1 is associated with higher-risk myelodysplastic syndrome

[rok vydání 2020, impact factor 6.639 ]

Koralkova, P.; Belickova, M.; Kundrat, D.; Dostalova Merkerova, M.; Krejcik, Z.; Szikszai, K.; Kaisrlikova, M.; Vesela, J.; Vyhlidalova, P.; Stetka, J.; Hlavackova, A.; Suttnar, J.; Flodr, P.; Stritesky, J.; Jonasova, A.; Cermak, J.; Divoky, V.

Low plasma citrate levels and specific transcriptional signatures associated with quiescence of CD34+ progenitors predict Azacitidine therapy failure in MDS/AML patients

[rok vydání 2021, impact factor 6.639 ]

Zwierzina, H.; Suciu, S.; Loeffler-Ragg, J.; Neuwirtova, R.; Fenaux, P.; Beksac, M.; Harousseau, J.; Nuessler, V.; Cermak, J.; Solbu, G.; Willemze, R.; De Witte, T.; Amadori, S.

Low-dose cytosine arabinoside (LD-AraC) vs LD-AraC plus granulocyte/macrophage colony stimulating factor vs LD-AraC plus Interleukin-3 for myelodysplastic syndrome patients with a high risk of developing acute leukemia

[rok vydání 2008, impact factor 6.612]

Hrustincova, A.; Krejcik, Z.; Kundrat, D.; Szikszai, K.; Belickova, M.; Pecherkova, P.; Klema, J.; Vesela, J.; Hruba, M.; Cermak, J.; Hrdinova, T.; Krijt, M.; Valka, J.; Jonasova, A.; Merkerova, M.D.

Circulating small noncoding RNAs have specific expression patterns in plasma and extracellular vesicles in myelodysplastic syndromes and are predictive of patient outcome

[rok vydání 2020, impact factor 6.600 ]

Hlaváčková, A.; Štikarová, J.; Pimková, K.; Chrastinová, L.; Májek, P.; Kotlín, R.; Čermák, J.; Suttnar, J.; Dyr, J.E.

Enhanced plasma protein carbonylation in patients with myelodysplastic syndromes

[rok vydání 2017, impact factor 6.020 ]

Broseus, J.; Florensa, L.; Zipperer, E.; Schnittger, S.; Malcovati, L.; Richebourg, S.; Lippert, E.; Cermak, J.; Evans, J.; Mounier, M.; Raya, J.M.; Bailly, F.; Gattermann, N.; Haferlach, T.; Garand, R.; Allou, K.; Besses, C.; Germing, U.; Haferlach, C.; Travaglino, E.; Luno, E.; Pinan, M.A.; Arenillas, L.; Rozman, M.; Sirvent, M.L.P.; Favre, B.; Guy, J.; Alonso, E.; Ahwij, N.; Jerez, A.; Hermouet, S.; Maynadié, M.; Cazzola, M.; Girodon, F.

Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis

[rok vydání 2012, impact factor 5.935 ]

Votavova, H.; Urbanova, Z.; Kundrat, D.; Dostalova Merkerova, M.; Vostry, M.; Hruba, M.; Cermak, J.; Belickova, M.

Modulation of the immune response by deferasirox in myelodysplastic syndrome patients

[rok vydání 2021, impact factor 5.863 ]

de Swart, L.; Smith, A.; Johnston, T.W.; Haase, D.; Droste, J.; Fenaux, P.; Symeonidis, A.; Sanz, G.; Hellström-Lindberg, E.; Čermák, J.; Germing, U.; Stauder, R.; Georgescu, O.; MacKenzie, M.; Malcovati, L.; Holm, M.; Almeida, A.M.; Madry, K.; Slama, B.; Guerci-Bresler, A.; Sanhes, L.; Beyne-Rauzy, O.; Luno, E.; Bowen, D.; de Witte, T.

Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry

[rok vydání 2015, impact factor 5.812 ]

Merkerova, M.D.; Remesova, H.; Krejcik, Z.; Loudova, N.; Hrustincova, A.; Szikszai, K.; Cermak, J.; Jonasova, A.; Belickova, M.

Relationship between altered miRNA expression and DNA methylation of the DLK1-DIO3 region in azacitidine-treated patients with myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes

[rok vydání 2018, impact factor 5.656 ]

Belickova, M.; Vesela, J.; Jonasova, A.; Pejsova, B.; Votavova, H.; Dostalova Merkerova, M.; Zemanova, Z.; Brezinova, J.; Mikulenkova, D.; Lauermannova, M.; Valka, J.; Michalova, K.; Neuwirtova, R.; Cermak, J.

TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes

[rok vydání 2016, impact factor 5.168 ]

Cermak, J.; Balla, J.; Jacob, H.S.; Balla, G.; Enright, H.; Nath, K.; Vercellotti, G.M.

Tumor cell heme uptake induces ferritin synthesis resulting in altered oxidant sensitivity : possible role in chemotherapy efficacy

[rok vydání 2006, impact factor 5.156]

Svobodova, K.; Lhotska, H.; Hodanova, L.; Pavlistova, L.; Vesela, D.; Belickova, M.; Vesela, J.; Brezinova, J.; Sarova, I.; Izakova, S.; Lizcova, L.; Siskova, M.; Jonasova, A.; Cermak, J.; Michalova, K.; Zemanova, Z.

Cryptic aberrations may allow more accurate prognostic classification of patients with myelodysplastic syndromes and clonal evolution

[rok vydání 2020, impact factor 5.006 ]

Štikarová, J.; Suttnar, J.; Pimková, K.; Chrastinová-Mášová, L.; Čermák, J.; Dyr, J.E.

Enhanced levels of asymmetric dimethylarginine in a serum of middle age patients with myelodysplastic syndrome

[rok vydání 2013, impact factor 4.933 ]

Belickova, M.; Merkerova, M.D.; Stara, E.; Vesela, J.; Sponerova, D.; Mikulenkova, D.; Brdicka, R.; Neuwirtova, R.; Jonasova, A.; Cermak, J.

DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population

[rok vydání 2013, impact factor 4.933 ]

Mojzikova, R.; Koralkova, P.; Holub, D.; Zidova, Z.; Pospisilova, D.; Cermak, J.; Striezencova Laluhova, Z.; Indrak, K.; Sukova, M.; Partschova, M.; Kucerova, J.; Horvathova, M.; Divoky, V.

Iron status in patients with pyruvate kinase deficiency: neonatal hyperferritinaemia associated with a novel frameshift deletion in the PKLR gene (p.Arg518fs), and low hepcidin to ferritin ratios

[rok vydání 2014, impact factor 4.711 ]

Plasilova, M.; Zivny, J.; Jelinek, J.; Neuwirtova, R.; Cermak, J.; Necas, E.; Andera, L.; Stopka, T.

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

[rok vydání 2006, impact factor 4.693]